Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer
- PMID: 32209136
- PMCID: PMC7092527
- DOI: 10.1186/s13047-020-00383-2
Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer
Abstract
Background: In 2007, we reported a summary of data comparing diabetic foot complications to cancer. The purpose of this brief report was to refresh this with the best available data as they currently exist. Since that time, more reports have emerged both on cancer mortality and mortality associated with diabetic foot ulcer (DFU), Charcot arthropathy, and diabetes-associated lower extremity amputation.
Methods: We collected data reporting 5-year mortality from studies published following 2007 and calculated a pooled mean. We evaluated data from DFU, Charcot arthropathy and lower extremity amputation. We dichotomized high and low amputation as proximal and distal to the ankle, respectively. This was compared with cancer mortality as reported by the American Cancer Society and the National Cancer Institute.
Results: Five year mortality for Charcot, DFU, minor and major amputations were 29.0, 30.5, 46.2 and 56.6%, respectively. This is compared to 9.0% for breast cancer and 80.0% for lung cancer. 5 year pooled mortality for all reported cancer was 31.0%. Direct costs of care for diabetes in general was $237 billion in 2017. This is compared to $80 billion for cancer in 2015. As up to one-third of the direct costs of care for diabetes may be attributed to the lower extremity, these are also readily comparable.
Conclusion: Diabetic lower extremity complications remain enormously burdensome. Most notably, DFU and LEA appear to be more than just a marker of poor health. They are independent risk factors associated with premature death. While advances continue to improve outcomes of care for people with DFU and amputation, efforts should be directed at primary prevention as well as those for patients in diabetic foot ulcer remission to maximize ulcer-free, hospital-free and activity-rich days.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk.J Diabetes Complications. 2014 Sep-Oct;28(5):632-8. doi: 10.1016/j.jdiacomp.2014.04.011. Epub 2014 Apr 24. J Diabetes Complications. 2014. PMID: 24877985 Free PMC article.
-
Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?Clin Orthop Relat Res. 2020 Dec;478(12):2869-2888. doi: 10.1097/CORR.0000000000001416. Clin Orthop Relat Res. 2020. PMID: 32694315 Free PMC article.
-
Amputation and mortality frequencies associated with diabetic Charcot foot arthropathy: a meta-analysis.Foot Ankle Surg. 2022 Dec;28(8):1170-1176. doi: 10.1016/j.fas.2022.08.004. Epub 2022 Aug 13. Foot Ankle Surg. 2022. PMID: 36028441 Review.
-
Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study.J Foot Ankle Res. 2019 Jun 14;12:34. doi: 10.1186/s13047-019-0345-y. eCollection 2019. J Foot Ankle Res. 2019. PMID: 31223342 Free PMC article.
-
The costs of diabetic foot: the economic case for the limb salvage team.J Vasc Surg. 2010 Sep;52(3 Suppl):17S-22S. doi: 10.1016/j.jvs.2010.06.003. J Vasc Surg. 2010. PMID: 20804928 Review.
Cited by
-
Missed Appointments and the Potential Correlation between Personal Characteristics, Personality, and Familial Characteristics and Missed Appointments for Adults with Diabetes Mellitus at the Primary Care Unit of Khon Kaen Province.Healthcare (Basel). 2024 Oct 6;12(19):1992. doi: 10.3390/healthcare12191992. Healthcare (Basel). 2024. PMID: 39408172 Free PMC article.
-
Retention processed placental membrane versus standard of care in treating diabetic foot ulcers.Int Wound J. 2024 Oct;21(10):e70096. doi: 10.1111/iwj.70096. Int Wound J. 2024. PMID: 39402007 Free PMC article.
-
DFUCare: deep learning platform for diabetic foot ulcer detection, analysis, and monitoring.Front Endocrinol (Lausanne). 2024 Sep 23;15:1386613. doi: 10.3389/fendo.2024.1386613. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39381435 Free PMC article.
-
Effects of different treatment measures on the efficacy of diabetic foot ulcers: a network meta-analysis.Front Endocrinol (Lausanne). 2024 Sep 23;15:1452192. doi: 10.3389/fendo.2024.1452192. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39377075 Free PMC article. Review.
-
Association of Race With Referral Disparities for Patients With Diabetic Foot Ulcers at an Institution Serving Rural and Urban Populations.Foot Ankle Orthop. 2024 Sep 28;9(3):24730114241281335. doi: 10.1177/24730114241281335. eCollection 2024 Jul. Foot Ankle Orthop. 2024. PMID: 39371683 Free PMC article.
References
-
- Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367–2375. - PubMed
-
- Infection guideline - IWGDF Guidelines. IWGDF Guidelines. https://iwgdfguidelines.org/infection-guideline/. Published May 25, 2019. Accessed December 22, 2019.
-
- Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18–25. - PubMed
-
- IDF Diabetes Atlas 9th edition 2019. https://diabetesatlas.org/en/. Accessed December 6, 2019. - PubMed
-
- Wukich DK, Raspovic KM, Suder NC. Patients with diabetic foot disease fear major lower-extremity amputation more than death. Foot Ankle Spec. 2018;11(1):17–21. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials